Molecular genetics of idiopathic pulmonary fibrosis by R. N. Mustafin

“…Idiopathic pulmonary fibrosis (IPF) is a severe progressive interstitial lung disease with a prevalence of 2 to 29 per 100,000 of the world’s population. …”
Get full text

Brain Oxygenation During Exercise in Different Types of Chronic Lung Disease: A Narrative Review by Stella Kritikou, Andreas Zafeiridis, Georgia Pitsiou, Ioannis Gkalgkouranas, Leonidas Kastritseas, Afroditi Boutou, Konstantina Dipla

“…Chronic lung diseases such as Chronic Obstructive Pulmonary Disease, Interstitial Lung Disease (ILD), and Pulmonary Hypertension (PH) are characterized by progressive symptoms such as dyspnea, fatigue, and muscle weakness, often leading to physical inactivity, and reduced quality of life. …”
Get full text

A Case of Polymyxin b-Immobilized Fiber Column Treatment for Rapidly Progressive Interstitial Pneumonia Associated with Clinically Amyopathic Dermatomyositis by Oh Sasaki, Makoto Dohi, Hiroaki Harada, Mitsuru Imamura, Yumi Tsuchida, Kensuke Yamaguchi, Toshihiko Komai, Kazuhiko Yamamoto

“…Initial treatment with pulsed corticosteroids and cyclophosphamide, intravenous immunoglobulin, and cyclosporine seemed to suppress the activity of interstitial lung disease temporarily, but signs of relapse were detected such as elevation of serum KL-6 level and progressing pulmonary shadows in chest computed tomography scan. …”
Get full text

Respiratory patient experience of measures to reduce risk of COVID-19: findings from a descriptive cross-sectional UK wide survey by Andrew Cumella, Nicholas S Hopkinson, Michael Laffan, Joe Farrington-Douglas, Keir EJ Philip

“…Long-term respiratory conditions reported included asthma (83%), chronic obstructive pulmonary disease (10%), bronchiectasis (4%), interstitial lung disease (2%) and ‘other’ (<1%) (eg, lung cancer and pulmonary endometriosis).Outcome measures Study responses related to impacts on key elements of healthcare, as well as practical, psychological and social consequences related to the COVID-19 pandemic and social distancing measures.Results 45% reported disruptions to care, including cancellations of appointments, investigations, pulmonary rehabilitation, treatment and monitoring. …”
Get full text

Managing Post COVID-19 Patient with Breathlessness by Yen Shen Wong, Muhammad Amin Ibrahim, Mohd Arif Mohd Zim, Mohd Fauzi Abdul Rani

“…These groups of patients should be closely followed up to unmask interstitial lung disease that may present prior to COVID-19 and worsen post-infection. …”
Get full text

Helicobacter Pylori infection in systemic sclerosis and its association with upper gastrointestinal dysfunction by Chilukuri Balaji, Mahendran Bhuvanesh, Chinnadurai Saranya, Ramamoorthy Ramesh, Mayilsamy Saravanan, Sankaralingam Rajeswari

“…Anti-H. pylori IgG antibody levels showed no correlation with disease duration, erythrocyte sedimentation rate, C-reactive protein, interstitial lung disease, and modified Rodnan Skin Score. …”
Get full text

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database by Tingting Jiang, Yanping Li, Ni Zhang, Lanlan Gan, Hui Su, Guiyuan Xiang, Yuanlin Wu, Yao Liu

“…For gilteritinib, 29 positive signals for AEs not mentioned in its instructions were identified, such as cerebral hemorrhage, tumor lysis syndrome, and interstitial lung disease. Midostaurin exhibited 24 positive signals for AEs not listed in its instructions, including neutropenic colitis, neutropenic sepsis, and septic shock. …”
Get full text

Tomographic presentation with miliary appearance in an immunocompromised patient with pulmonary candidiasis: A case report by Luis Alejandro Rodríguez-Hidalgo, Diana Cecilia Ruiz-Caballero, César Augusto Colunche-Narváez, Amalia Guadalupe Vega-Fernández, Theresina Elizabeth Rodríguez-Sáenz

“…Chest tomography revealed miliary interstitial lung disease, and he was prescribed antituberculosis treatment. …”
Get full text

Longitudinal validation of King's Sarcoidosis Questionnaire in a prospective cohort with mild sarcoidosis by Janne Møller, Thomas Skovhus Prior, Ole Hilberg, Surinder Birring, Elisabeth Bendstrup

“…Results In patients (n=150), the KSQ had moderate to strong correlations with the Short Form-12 (Mental Component Summary), the King's Brief Interstitial Lung Disease questionnaire and the Fatigue Assessment Scale (r=0.30–0.70) and weak correlations with the Short Form-12 (Physical Component Summary) and FVC (r=0.01–0.29). …”
Get full text

TRAIL-Dependent Resolution of Pulmonary Fibrosis by David M. Habiel, Ana Paula Moreira, Ugur B. Ismailoglu, Michael P. Dunleavy, Karen A. Cavassani, Nico van Rooijen, Ana Lucia Coelho, Cory M. Hogaboam

“…Idiopathic pulmonary fibrosis (IPF) is the most common form of interstitial lung disease characterized by the persistence of activated myofibroblasts resulting in excessive deposition of extracellular matrix proteins and profound tissue remodeling. …”
Get full text

Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report by Tomoki Kozono, Kentaro Tanaka, Tomoko Yagi, Kazuto Kamikawaji, Masaki Watanabe, Azusa Iwanaga, Minako Hamada, Yoshifusa Koreeda, Hiromasa Inoue, Ikkou Higashimoto

“…APAP coexisting with autoimmune diseases may often be misdiagnosed as connective tissue disease–associated interstitial lung disease (ILD). Here, we describe a rare case of a patient with systemic sclerosis who was diagnosed with APAP after the exacerbation of lung opacities during treatment with immunosuppressive agents. …”
Get full text

From fibrosis to granuloma: drug induced systemic sarcoidosis-like reaction after rituximab in a patient with primary Sjögren’s syndrome by Rui Rua Coelho, Sara Xavier Pires, José Ricardo Brandão, Inês Furtado

“…Moreover, granulomatous lymphocytic interstitial lung disease associated with common variable immunodeficiency and immune reconstitution syndrome in patients wirh human immunodeficiency virus show clinical similarities to DISR and can help unveil new cytogenic and physiologic pathways. …”
Get full text

Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease by Natalie K. Kozij, John T. Granton, Philip E. Silkoff, John Thenganatt, Shobha Chakravorty, Sindhu R. Johnson

“…Exhaled nitric oxide (eNO) is a potential biomarker to distinguish systemic sclerosis (SSc) associated pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). We evaluated the discriminative validity, feasibility, methods of eNO measurement, and magnitude of differences across lung diseases, disease-subsets (SSc, systemic lupus erythematosus), and healthy-controls. …”
Get full text

Quality of life in idiopathic pulmonary fibrosis in Latin American countries by H. Aguilar-Duran, M. Fernández, M. González-García, E. Rincón-Alvarez, M. Alberti, F. Caro, E. Tavera, E. Vásquez, N. Cortez, M. Salinas, M. Florenzano, C. Florestano, Ivette Buendia-Roldan

“…Abstract Background Idiopathic pulmonary fibrosis (IPF) is the most common Interstitial Lung Disease (ILD). It is characterized by dyspnoea and a progressive decline in lung function, which negatively affects life. …”
Get full text

Evaluation of e-Lung automated quantitative computed tomography biomarkers in idiopathic pulmonary fibrosis by Peter M. George, Christian Rennison-Jones, Giacomo Benvenuti, Aliki Sifostratoudaki, Finja A. Ottink, Wassim Bou-Zeid, Roberta E. Ledda, Roqia F. Abul Kadir, Bushra Johari, Claire Fernandez, George W.J. Harston, Olivier Joly, Stephen Gerry, Anand Devaraj

Get full text

Significance of N-terminal pro-B-type natriuretic peptide levels in lung cancer by Sinem İnan, Semra Bilaçeroğlu, Burcu Uludağ Artun

“…A total of 105 lung cancer and 120 control patients (chronic obstructive lung disease, interstitial lung disease, pulmonary thromboembolism, and pneumonia; 30/subgroup) with measured NT-proBNP levels were included retrospectively. …”
Get full text

Profiles of systemic lupus erythematosus patients with co-existing sickle cell disease: a coincidence or true association? by Hakeem Babatunde Olaosebikan, Etseoghena Igebu, Adebukola Khairat Orolu, Gbenga Joshua Odunlami, Ilo Azizat Bamisebi, Akin Dada, Ebele Uche, Olufemi Adelowo

“…Two are on maintenance hemodialysis, one with interstitial lung disease, and one on long-term anticoagulation due to deep vein thrombosis. …”
Get full text

A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system by Ke He, Kaidi Zhao, Tingyi Yin, Meng Liu, Jiashu Liu, Wenqian Du, Xinyi Liu, Baochen Cheng, Dewu Zhang, Yan Zheng

“…Additionally, we found potential adverse reactions not noted on the drug’s label that exhibited positive signals, including depression, increased blood pressure, peripheral swelling, gait disturbance, inability to walk, stress, myocardial infarction, sepsis, uveitis, nephrolithiasis, and interstitial lung disease. Moreover, this analysis highlighted the critical need for vigilant monitoring of adverse events, especially during the first month following the initiation of treatment. …”
Get full text

The role of the microbiota and metabolites in the treatment of pulmonary fibrosis with UC-MSCs: Integrating fecal metabolomics and 16S rDNA analysis. by Yukai Luo, Shuang Zhou, Xiaojing Zhang, Yijian Lin, Jun Liu, Wenzhao Cheng, Yiming Zeng

“…<h4>Introduction</h4>Pulmonary fibrosis (PF) is a chronic and irreversible interstitial lung disease characterized by a lack of effective therapies. …”
Get full text

The Frequency of Epidermal Growth Factor Receptor Mutation of Nonsmall Cell Lung Cancer according to the Underlying Pulmonary Diseases by Kazuhiro Usui, Tomonori Ushijima, Yoshiaki Tanaka, Chiharu Tanai, Hiromichi Noda, Norifumi Abe, Hajime Horiuchi, Teruo Ishihara

“…Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in patients with nonsmall cell lung cancer with epidermal growth factor receptor (EGFR) mutation, EGFR-TKIs have a risk of inducing fatal interstitial lung disease (ILD). The selection of chemotherapy based on the EGFR mutation status is recommended, however, the frequency of EGFR mutation in patients with ILD and the efficacy and safety of EGFR-TKI in patients with ILD and EGFR mutation are unknown. …”
Get full text